Psoriatic arthritis (active) - ustekinumab (Rapid Rev TA313): committee papers
Table of Contents
- 01 - Technology appraisal guidance TA313
- 02 - Patient Access Scheme (PAS) submission the technology Manufacturer - Janssen
- 03 - Evidence Review Group critique prepared by the Centre for Reviews and Dissemination and Centre for Health Economics
As this is a rapid review, the documents and their titles do not match those usually included in the committee papers. Please get in touch if you have any queries about this upload request.
|
Psoriatic arthritis (active) - ustekinumab (Rapid Rev TA313): committee papers
09 December 2014 (1.82 Mb 3 sec) |
This page was last updated: 09 December 2014